STAT Plus Insurer accuses J&J unit of using sham patent litigation to extend monopoly on cancer drug

STAT Plus: Insurer accuses J&J unit of using ‘sham’ patent litigation to extend monopoly on cancer drug

An insurer has filed a lawsuit accusing a J&J subsidiary of filing "sham" patent litigation in a bid to unfairly thwart generic competition to its best-selling prostate cancer treatment.

More From BioPortfolio on "STAT Plus: Insurer accuses J&J unit of using ‘sham’ patent litigation to extend monopoly on cancer drug"